SF Healthcare Week: Vera Therapeutics’ announced this week that the FDA accepted the company’s filing for atacicept, a potential new treatment for IgA Nephropathy
BiotechTV - News
00:00
Phase II/III Data Consistency and Confidential GFR
Marshall highlights consistent Phase II/III design, improved interim numbers, and confidential ongoing GFR data.
Play episode from 04:23
Transcript
